| Literature DB >> 10334209 |
G A Boorman1, L E Anderson, J E Morris, L B Sasser, P C Mann, S L Grumbein, J R Hailey, A McNally, R C Sills, J K Haseman.
Abstract
Several studies have suggested that exposure to 50 Hz magnetic fields promote chemically induced breast cancer in rats. Groups of 100 female Sprague-Dawley rats were initiated with a single 10 mg gavage dose of 7,12-dimethylbenz[a]anthracene (DMBA) at 50 days of age followed by exposure to ambient fields (sham exposed), 50 Hz magnetic fields at either 1 or 5 Gauss (G) field intensity or 60 Hz fields at 1 G for 18.5 h/day, 7 days/week for 26 weeks. A vehicle control group without DMBA was included. Rats were palpated weekly for the presence of tumors. There was no effect of magnetic field exposure on body weight gains or the time of appearance of mammary tumors. At the end of 26 weeks, the animals were killed and the mammary tumors counted and measured. Mammary gland masses found grossly were examined histologically. The mammary gland carcinoma incidence was 96, 90, 95 and 85% (P < 0.05, decrease) for the DMBA controls, 1 G 50 Hz, 5 G 50 Hz and 1 G 60 Hz groups, respectively. The total numbers of carcinomas were 649, 494 (P < 0.05, decrease), 547 and 433 (P < 0.05, decrease) for the DMBA controls, 1 G 50 Hz, 5 G 50 Hz and 1 G 60 Hz groups, respectively. The number of fibroadenomas varied from 276 to 319, with the lowest number in the 1 G 60 Hz exposure group. Measurement of the tumors revealed no difference in tumor size between groups. In this breast cancer initiation-promotion study in female Sprague-Dawley rats, there was no evidence that 50 or 60 Hz magnetic fields promoted breast cancer under the conditions of this assay. This study does not support the hypothesis that magnetic field exposure can promote breast cancer in this rat model.Entities:
Mesh:
Substances:
Year: 1999 PMID: 10334209 PMCID: PMC7109974 DOI: 10.1093/carcin/20.5.899
Source DB: PubMed Journal: Carcinogenesis ISSN: 0143-3334 Impact factor: 4.944
Experimental design
| Group | Initiation | Promotion | Carcinogenicity study | Melatonin studya |
|---|---|---|---|---|
| aTen animals per group were killed for analysis of serum and pineal melatonin at weeks 4, 8 and 12; these results are reported separately. | ||||
| bVehicle controls received 1 ml of sesame oil. | ||||
| cRats not exposed to magnetic fields have ambient field intensities of <1 mG. | ||||
| Vehicleb | None | Nonec | 100 | 30 |
| DMBA | 10 mg DMBA | Nonec | 100 | 30 |
| 1 G 50 Hz | 10 mg DMBA | 1 G 50 Hz | 100 | 30 |
| 5 G 50 Hz | 10 mg DMBA | 5 G 50 Hz | 100 | 30 |
| 1 G 60 Hz | 10 mg DMBA | 1 G 60 Hz | 100 | 30 |
Summary of exposure field measurements
| Condition | Start of study | End of study | ||
|---|---|---|---|---|
| Mean ± SDa | Range | Mean ± SD | Range | |
| aField intensity in G. There were two measurements in the control room but neither value exceeded 1 mG; control values are shown for the East monitor. | ||||
| 5 G 50 Hz | 5.0± 0.2 | 4.6–5.4 | 5.1± 0.2 | 4.6–5.4 |
| 1 G 50 Hz | 1.0± 0.1 | 0.9–1.1 | 1.0± 0.1 | 0.9–1.1 |
| 1 G 60 Hz | 1.0± 0.0 | 0.9–1.1 | 1.0± 0.0 | 0.9–1.1 |
| DMBA control | 0.0005 ± 0.0001 | 0.0003–0.0006 | 0.0002 ± 0.0001 | 0.0001–0.0003 |
Fig. 1. Growth curves for female rats receiving either vehicle control or DMBA followed by sham or magnetic field exposure.
Fig. 2.Cumulative proportion of female rats with palpable mammary gland tumors during the 26 week DMBA initiation/magnetic field promotion study.
Fig. 3. Mean number of mammary gland tumors per tumor-bearing rat during the 26 week DMBA initiation/magnetic field promotion study.
Evaluation of tumor size and multiplicity
| Diagnoses | DMBA plus magnetic field exposure group | |||
|---|---|---|---|---|
| Control | 1 G 50 Hz | 5 G 50 Hz | 1 G 60 Hz | |
|
a
| ||||
|
| ||||
| Tumors per tumor bearing rat | 2.8 ± 2.4 | 2.4 ± 1.5 | 2.8 ± 2.5 | 2.3 ± 1.7 |
| Mean tumor size (cm2) | 1.3 ± 0.7 | 1.3 ± 0.8 | 1.5 ± 0.9 | 1.3 ± 0.8 |
|
| ||||
| Tumors per tumor bearing rat | 6.0 ± 4.1 | 5.3 ± 3.8 | 5.6 ± 3.8 | 4.8 ± 4.0 |
| Mean tumor size (cm2) | 1.3 ± 0.9 | 1.3 ± 0.9 | 1.4 ± 1.0 | 1.4 ± 1.0 |
|
| ||||
| Fibroadenoma per rat | 3.2 ± 4.4 | 3.2 ± 4.5 | 3.2 ± 3.9 | 2.8 ± 3.9 |
| Total fibroadenoma area (cm2) | 391.1 | 361.6 | 426.6 | 321.2 |
| Mean area per fibroadenoma (cm2) | 1.2 | 1.1 | 1.3 | 1.2 |
| Fibroadenoma area per rat (cm2) | 3.9 ± 6.9 | 3.6 ± 7.4 | 4.3 ± 8.9 | 3.2 ± 5.9 |
| Carcinoma per rat | 6.5 ± 4.8 | 4.9 ± 4.2b | 5.5 ± 3.9 | 4.3 ± 3.9a |
| Total carcinoma area (cm2) | 1731.6 | 1435.5 | 1815.0 | 1366.0 |
| Mean area per carcinoma (cm2) | 2.7 | 2.9 | 3.3 | 3.2 |
| Carcinoma area per rat (cm2) | 17.3 ± 16.3 | 14.4 ± 16.6 | 18.2 ± 18.0 | 13.7 ± 18.1 |
Fig. 4. Mean mammary tumor size per tumor-bearing rat estimated by palpation during the in-life phase of the 26 week DMBA initiation/magnetic field promotion study.
Fig. 5. Fibroadenoma in a female rat exposed to DMBA followed by magnetic field exposure. There are islands of glandular cells separated by dense fibrous tissue giving the tumor a lobular appearance. H&E stain; magnification ×132.
Fig. 6. Carcinoma in a female rat exposed to DMBA followed by magnetic field exposure. H&E stain; magnification ×264.
Evaluation of tumor incidence
| Diagnoses | DMBA plus magnetic field exposure group | |||
|---|---|---|---|---|
| Controla | 1 G 50 Hz | 5 G 50 Hz | 1 G 60 Hz | |
| aNumber of rats with diagnosis (100 animals examined per group). | ||||
|
b
| ||||
| Adenoma | 2 | 0 | 0 | 0 |
| Carcinoma | 96 | 90 | 95 | 85b |
| Fibroadenoma | 71 | 76 | 73 | 68 |
Fig. 7. Total number of fibroadenomas and carcinomas found in female rats receiving DMBA followed by sham or magnetic field exposure. Three vehicle control rats had fibroadenomas and two had carcinomas (data not shown).